Article

Lessons learned and implications of early therapies for coronavirus disease in a territorial service center in the Calabria region

2022-08-01

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Monoclonal antibodies (mAbs) and antivirals have been approved for early therapy of<bold> </bold>coronavirus disease (COVID-19), however, in the real-life setting, there are difficulties to prescribe these therapies within few days from symptom onset as recommended, and effectiveness of combined use of these drugs have been hypothesized in most-at-risk patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cdb33364-1bcb-575d-9c61-4e0aa7589723
DOI: 10.21203/rs.3.rs-1877872/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lessons learned and implications of early therapies for coronavirus disease in a territorial service center in the Calabria regionDOI 10.21203/rs.3.rs-1877872/v1Read

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity Read

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read

Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, ChinaSemantic proximity Read

Clinical Characteristics of Mild/moderate COVID-19 Patients with a Prolonged Negative Conversion Time of SARS-CoV-2 Nucleic Acid DetectionSemantic proximity Read

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity Read

Cancer inpatient with COVID-19: a report from the Brazilian National Cancer InstituteSemantic proximity Read

Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 OutpatientsSemantic proximity Read

Multicenter cohort study of the risk factors and mortality of Omicron variant SARS-CoV-2-infected patients with hematologic malignancies in hospitalsSemantic proximity Read

Prevalence and Incidence of Antibodies Against Sars-Cov-2 Among Primary Healthcare Providers in Belgium During One Year of the Covid-19 Epidemic: Prospective Cohort Study ProtocolSemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron SurgeSemantic proximity Read

Case Report: Longitudinal assessment of a COVID-19 patient in the midst of a pandemicSemantic proximity Read